Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

After Pandemic, US FDA Commissioner Wants To Continue ‘Rolling Review’ Offered To COVID-19 Products

Executive Summary

Stephen Hahn also said the expedited approval process could be even more efficient.

You may also be interested in...



‘Most People Are Going To Get COVID’: US FDA’s Woodcock Not Ready To Shift To Endemic Policy

Acting FDA commissioner tell Senate committee that federal priority should be to ensure essential services remain functional as the Omicron variant’s spread continues.

Would An Independent Analysis Of US FDA's Pandemic Response Find Transformative Effect?

Group of outside experts could help the agency determine the pandemic-inspired practices and regulatory changes to keep, former commissioner von Eschenbach says.

Does US FDA Need An Independent Commission To Analyze Its Pandemic Response?

Group of outside experts could help the agency determine the pandemic-inspired practices and regulatory changes to keep, former commissioner von Eschenbach says.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS143098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel